Brain Tumors

Tailored Therapy in Diffuse Gliomas

We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.

Brain Tumors

The US Food and Drug Administration has approved dinutuximab (Unituxin) for the treatment of high-risk neuroblastoma in pediatric patients.

Expression of the IGF2BP1 gene was associated with more advanced tumors and decreased patient survival in neuroblastoma, suggesting its prognostic value.

Researchers have shown that reprogramming T cells to target glioblastoma in mice resulted in control of these tumors.

A new study finds that childhood cancer survivors are at risk for pituitary hormone deficiencies after radiotherapy treatment to the head.

Stable, long-term survivors of low-grade glioma were able to maintain a high level of quality of life, but did experience detectable declines in certain areas.

Researchers have identified two genetic characteristics that may distinguish pediatric secondary high-grade glioma from primary high-grade glioma.

A history of hormonal contraceptive use in younger women for 5 years or more was found to be associated with a possible increased risk of glioma.


Subscribe to Brain Tumors on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.